Novastan (Argatroban Monohydrate)

Argatroban, the active ingredient in Novastan, is a direct thrombin inhibitor presented as an intravenous solution for IV use. It is employed to provide anticoagulation in patients with heparin‑induced thrombocytopenia, during percutaneous coronary interventions, and for the prevention and treatment of thrombosis. GNH USA supplies Novastan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and pharmacies worldwide.

Novastan is a direct thrombin inhibitor used in clinical settings that require precise anticoagulation control. - Heparin‑induced thrombocytopenia (HIT): provides effective anticoagulation when heparin therapy is contraindicated. - Percutaneous coronary intervention (PCI): maintains anticoagulation throughout the coronary procedure to prevent clot formation. - Prevention and treatment of thrombosis: reduces the risk of new clot development in patients at high thrombotic risk.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects: - Bleeding: ranging from minor bruising to moderate hemorrhage. - Thrombocytopenia: reduced platelet count observed during treatment. - Anemia: mild decrease in hemoglobin levels. - Nausea or vomiting. - Headache. - Fever or chills.

Serious or Rare Side Effects: - Severe hemorrhage: life‑threatening internal bleeding. - Anaphylactic reaction: sudden onset of rash, swelling, and respiratory distress. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Cardiac arrest or severe hypotension. - Paradoxical thrombosis: rare clot formation despite anticoagulation. - Immune‑mediated hemolytic anemia.

When using Novastan, clinicians should observe several safety measures. - Monitor bleeding: assess for signs of excessive hemorrhage during therapy. - Assess coagulation parameters: regularly check activated clotting time or aPTT. - Adjust dose in hepatic impairment: reduce infusion rate in patients with liver dysfunction. - Use caution in renal impairment: monitor renal function despite primary hepatic clearance. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Argatroban may interact with other agents that affect hemostasis.

Major Interactions (Avoid): - Concomitant anticoagulants (e.g., heparin, warfarin): markedly increased bleeding risk. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise Argatroban plasma levels. - Other direct thrombin inhibitors (e.g., dabigatran): additive anticoagulant effect. - Fibrinolytic agents (e.g., alteplase): heightened hemorrhagic potential. - Antiplatelet drugs (e.g., clopidogrel, aspirin): synergistic increase in bleeding.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen): may exacerbate gastrointestinal bleeding. - Certain antibiotics (e.g., macrolides, fluoroquinolones): modest effect on metabolism. - Herbal supplements (e.g., ginkgo biloba, garlic): potential additive antithrombotic activity.